Transient Potent BCR-ABL Inhibition Is Sufficient to Commit Chronic Myeloid Leukemia Cells Irreversibly to Apoptosis

Cancer Cell

Volumn 14, Issue 6, 2008, Pages 485-493

  Shah, Neil P ^a   Kasap, Corynn ^a   Weier, Christopher ^a   Balbas, Minna ^b   Nicoll, John M ^c   Bleickardt, Eric ^d   Nicaise, Claude ^d   Sawyers, Charles L ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d BRISTOL MYERS SQUIBB   (United States)

Author keywords

CELLCYCLE

Indexed keywords

BCR ABL PROTEIN; BIM PROTEIN; DASATINIB; ERLOTINIB; IMATINIB; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; CANCER REGRESSION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG CYTOTOXICITY; DRUG HALF LIFE; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG TARGETING; ENZYME INHIBITION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL; LOW DRUG DOSE; PRIORITY JOURNAL; TREATMENT RESPONSE;

EID: 56849117387     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2008.11.001     Document Type: Article

References (23)

1. Amann J., Kalyankrishna S., Massion P.P., Ohm J.E., Girard L., Shigematsu H., Peyton M., Juroske D., Huang Y., Stuart Salmon J., et al. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res. 65 (2005) 226-235
2. Brave M., Goodman V., Kaminskas E., Farrell A., Timmer W., Pope S., Harapanhalli R., Saber H., Morse D., Bullock J., et al. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin. Cancer Res. 14 (2008) 352-359
3. Burris III H.A., Hurwitz H.I., Dees E.C., Dowlati A., Blackwell K.L., O'Neil B., Marcom P.K., Ellis M.J., Overmoyer B., Jones S.F., et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J. Clin. Oncol. 23 (2005) 5305-5313
4. Carter T.A., Wodicka L.M., Shah N.P., Velasco A.M., Fabian M.A., Treiber D.K., Milanov Z.V., Atteridge C.E., Biggs III W.H., Edeen P.T., et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc. Natl. Acad. Sci. USA 102 (2005) 11011-11016
5. Cohen M.H., Williams G.A., Sridhara R., Chen G., McGuinn Jr. W.D., Morse D., Abraham S., Rahman A., Liang C., Lostritto R., et al. United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin. Cancer Res. 10 (2004) 1212-1218
6. Druker B.J., Tamura S., Buchdunger E., Ohno S., Segal G.M., Fanning S., Zimmermann J., and Lydon N.B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2 (1996) 561-566
7. Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M., Lydon N.B., Kantarjian H., Capdeville R., Ohno-Jones S., and Sawyers C.L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344 (2001) 1031-1037
8. Goodman V.L., Rock E.P., Dagher R., Ramchandani R.P., Abraham S., Gobburu J.V., Booth B.P., Verbois S.L., Morse D.E., Liang C.Y., et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin. Cancer Res. 13 (2007) 1367-1373
9. Gorre M.E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao P.N., and Sawyers C.L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293 (2001) 876-880
10. Johnson J.R., Cohen M., Sridhara R., Chen Y.F., Williams G.M., Duan J., Gobburu J., Booth B., Benson K., Leighton J., et al. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin. Cancer Res. 11 (2005) 6414-6421
11. Kane R.C., Farrell A.T., Saber H., Tang S., Williams G., Jee J.M., Liang C., Booth B., Chidambaram N., Morse D., et al. Sorafenib for the treatment of advanced renal cell carcinoma. Clin. Cancer Res. 12 (2006) 7271-7278
12. Kindler T., Breitenbuecher F., Kasper S., Stevens T., Carius B., Gschaidmeier H., Huber C., and Fischer T. In BCR-ABL-positive cells, STAT-5 tyrosine-phosphorylation integrates signals induced by imatinib mesylate and Ara-C. Leukemia 17 (2003) 999-1009
13. Kuroda J., Puthalakath H., Cragg M.S., Kelly P.N., Bouillet P., Huang D.C., Kimura S., Ottmann O.G., Druker B.J., Villunger A., et al. Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc. Natl. Acad. Sci. USA 103 (2006) 14907-14912
14. Milton D.T., Azzoli C.G., Heelan R.T., Venkatraman E., Gomez J.E., Kris M.G., Krug L.M., Pao W., Rizvi N.A., Dunne M., and Miller V.A. A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer. Cancer 107 (2006) 1034-1041
15. Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F., Kris M.G., and Varmus H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2 (2005) e73
16. Peng B., Hayes M., Resta D., Racine-Poon A., Druker B.J., Talpaz M., Sawyers C.L., Rosamilia M., Ford J., Lloyd P., and Capdeville R. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J. Clin. Oncol. 22 (2004) 935-942
17. Ren R., Ye Z.S., and Baltimore D. Abl protein-tyrosine kinase selects the Crk adapter as a substrate using SH3-binding sites. Genes Dev. 8 (1994) 783-795
18. Senechal K., Heaney C., Druker B., and Sawyers C.L. Structural requirements for function of the Crkl adapter protein in fibroblasts and hematopoietic cells. Mol. Cell. Biol. 18 (1998) 5082-5090
19. Shah N.P., Tran C., Lee F.Y., Chen P., Norris D., and Sawyers C.L. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305 (2004) 399-401
20. Shah N.P., Kantarjian H.M., Kim D.-W., Réa D., Dorlhiac-Llacer P.E., Milone J.H., Vela-Ojeda J., Silver R.T., Khoury H.J., Charbonnier A., et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J. Clin. Oncol. 26 (2008) 3204-3212
21. Sharma S.V., Gajowniczek P., Way I.P., Lee D.Y., Jiang J., Yuza Y., Classon M., Haber D.A., and Settleman J. A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell 10 (2006) 425-435
22. Talpaz M., Shah N.P., Kantarjian H., Donato N., Nicoll J., Paquette R., Cortes J., O'Brien S., Nicaise C., Bleickardt E., et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 354 (2006) 2531-2541
23. Weinstein I.B. Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 297 (2002) 63-64